<DOC>
	<DOCNO>NCT00532467</DOCNO>
	<brief_summary>This study second study evaluate SRX251 healthy volunteer represent first multiple dose study . The primary objective study evaluate safety tolerability escalate multiple oral dos SRX251 capsule 5 day healthy adult volunteer . Levels drug blood plasma also determine .</brief_summary>
	<brief_title>Multiple Dose Safety Study SRX251 Capsules Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>1 . Healthy subject age 18 55 year , inclusive . Subjects males nonpregnant , non lactate female nonchildbearing potential . 2 . Body mass index ( BMI ) 18.5 34.0 kg/m2 , inclusive , total body weight &gt; 50kg ( 110 pound ) . 3 . In good health determine medical history , baseline physical examination , vital sign , clinical laboratory test electrocardiogram ( ECG ) measurement . 4 . Subject willing able sign write informed consent prior begin study procedure . 5 . Subject willing able follow instruction , comply protocol requirement make require study visit . 1 . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . 2 . Pregnant lactating female , female childbearing potential , defined female postmenopausal ( postmenopausal female define female 45 55 year age must amenorrheic least 1 year PLUS serum FSH level within laboratory 's reference range postmenopausal woman ) female hysterectomy and/or bilateral oophorectomy and/or tubal ligation . 3 . Male subject willing either abstain sexual intercourse , use one follow method contraception first dose trial medication completion followup procedure . Male subject , without vasectomy , must use condom instructed female partner use another form contraception IUD , spermicidal foam/gel/film/cream/suppository , diaphragm spermicide , oral contraceptive , injectable progesterone , subdermal implant tubal ligation female partner could become pregnant time first dose trial medication completion followup procedure . 4 . Subject positive HIV , hepatitis B surface antigen hepatitis C antibody test screen . 5 . A general medical psychological condition behavior , include current substance dependence abuse , opinion investigator , might permit subject complete study sign inform consent . 6 . Any condition clinically significant abnormal finding physical examination , medical history , clinical laboratory result screen , opinion Principal Investigator , would make subject unsuitable study put additional risk . 7 . Inability understand follow study instruction . 8 . Known allergy hypersensitivity investigational study drug/placebo component . 9 . Treatment investigational drug within 30 day precede first study medication . 10 . Blood donation approximately 500 mL within 56 day prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>healthy volunteer</keyword>
</DOC>